Scpharmaceuticals (NASDAQ:SCPH) Stock Price Up 9.1%

Scpharmaceuticals Inc (NASDAQ:SCPH)’s stock price rose 9.1% during trading on Friday . The stock traded as high as $7.33 and last traded at $8.00, approximately 97,033 shares traded hands during trading. An increase of 54% from the average daily volume of 62,897 shares. The stock had previously closed at $7.33.

SCPH has been the topic of several recent research reports. Zacks Investment Research downgraded shares of Scpharmaceuticals from a “buy” rating to a “hold” rating in a research report on Thursday, January 30th. ValuEngine downgraded shares of Scpharmaceuticals from a “hold” rating to a “sell” rating in a research report on Tuesday, February 4th.

The firm’s 50-day moving average is $5.94 and its 200 day moving average is $5.67. The company has a current ratio of 10.48, a quick ratio of 10.47 and a debt-to-equity ratio of 0.34. The firm has a market capitalization of $126.71 million, a price-to-earnings ratio of -5.48 and a beta of 0.79.

Scpharmaceuticals (NASDAQ:SCPH) last posted its earnings results on Tuesday, November 12th. The company reported ($0.33) EPS for the quarter, topping the consensus estimate of ($0.45) by $0.12. Analysts predict that Scpharmaceuticals Inc will post -1.66 EPS for the current year.

In other news, CEO John H. Tucker purchased 5,000 shares of the company’s stock in a transaction dated Friday, December 13th. The shares were purchased at an average price of $5.24 per share, for a total transaction of $26,200.00. Following the transaction, the chief executive officer now owns 5,000 shares of the company’s stock, valued at $26,200. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. 4.07% of the stock is owned by company insiders.

Hedge funds and other institutional investors have recently modified their holdings of the company. Morgan Stanley lifted its position in shares of Scpharmaceuticals by 32.0% in the 2nd quarter. Morgan Stanley now owns 13,633 shares of the company’s stock worth $43,000 after purchasing an additional 3,306 shares during the period. 5AM Venture Management LLC acquired a new position in shares of Scpharmaceuticals in the 4th quarter worth approximately $18,414,000. Renaissance Technologies LLC lifted its position in shares of Scpharmaceuticals by 46.0% in the 4th quarter. Renaissance Technologies LLC now owns 163,677 shares of the company’s stock worth $926,000 after purchasing an additional 51,546 shares during the period. Jacobs Levy Equity Management Inc. lifted its position in shares of Scpharmaceuticals by 21.6% in the 4th quarter. Jacobs Levy Equity Management Inc. now owns 17,791 shares of the company’s stock worth $101,000 after purchasing an additional 3,157 shares during the period. Finally, Matisse Capital acquired a new position in shares of Scpharmaceuticals in the 3rd quarter worth approximately $86,000. Hedge funds and other institutional investors own 40.67% of the company’s stock.

About Scpharmaceuticals (NASDAQ:SCPH)

scPharmaceuticals Inc, a pharmaceutical company, engages in the development and commercialization of various pharmaceutical products. The company's lead product candidate is Furoscix that consists of proprietary subcutaneous formulation of furosemide, which is delivered through the SmartDose drug delivery system for treatment of congestion in decompensated heart failure patients outside of the acute care setting.

Further Reading: Market Indexes

Receive News & Ratings for Scpharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Scpharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.